Dr. Hafkin is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
PO Box 29750
Austin, TX 78755Phone+1 512-375-3485
Education & Training
The University of Texas Health Science Center at San AntonioClass of 1973
Certifications & Licensure
TX State Medical License 1973 - 2019
CA State Medical License 1977 - 2015
Clinical Trials
Publications & Presentations
PubMed
- 59 citationsAFN-1252, a FabI Inhibitor, Demonstrates a Staphylococcus-Specific Spectrum of ActivityJames A. Karlowsky, Nachum Kaplan, Barry Hafkin, Daryl J. Hoban, George G. Zhanel
Antimicrobial Agents and Chemotherapy. 2009-08-01 - 130 citationsWorldwide Assessment of Linezolid's Clinical Safety and Tolerability: Comparator-Controlled Phase III StudiesEthan Rubinstein, Raul E Isturiz, Harold C. Standiford, Leon G. Smith, Thomas H. Oliphant
Antimicrobial Agents and Chemotherapy. 2003-06-01 - 313 citationsHematologic Effects of Linezolid: Summary of Clinical ExperienceStanton L. Gerson, Sheldon L. Kaplan, Jon B. Bruss, Vu Le, Felix M. Arellano
Antimicrobial Agents and Chemotherapy. 2002-08-01
Press Mentions
MicuRx Enrolls First Patient in a Phase 2 Clinical Trial in U.S. For Novel Antibiotic, Contezolid AcefosamilNovember 26th, 2018
MicuRx Announces Receipt of FDA’s QIDP and Fast Track Designations for Contezolid and Contezolid AcefosamilSeptember 21st, 2018- MicuRx Initiates Phase 1 Clinical Trial in U.S. For Novel Antibiotic Agent MRX-4November 30th, 2016
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
